Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.
FPT155 is a soluble CD80 fusion protein. It stimulates anti-tumor immunity and efficiently co-stimulates potent anti-tumor activity in vivo, inducing a favorable microenvironment for an anti-tumor immune response.
FPT155 uses the binding interactions of soluble CD80 to:
- Directly engage CD28 to enhance its co-stimulatory activity (without super agonism)
- Block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation
FPT155 is being studied for the treatment of solid tumors. We anticipate initiating a Phase 1 clinical trial of FPT155 in Australia in the fourth quarter of 2018.